![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 42, 29583-29586, October 15, 1999
From the McArdle Laboratory for Cancer Research, University of Wisconsin Medical School, Madison, Wisconsin 53706
Understanding the mechanisms by which the
transcription rate of a particular gene is controlled is a common goal
of many investigators. A general approach taken to study
transcriptional regulation has been to first identify a protein-binding
site(s) using methods such as DNase footprinting or gel mobility shift
assays and then to remove the binding site(s) from its natural context
by placing single or multiple copies of the site(s) upstream of a
heterologous minimal promoter. This approach has the advantage that a
large degree of transcriptional activity can be observed when multiple copies of a factor are brought to a promoter that can recruit very few
other site-specific DNA-binding proteins. However, analysis of
synthetic promoter constructs provides information concerning what a
transcription factor has the potential to do but does not necessarily
provide information about the specific contribution of a factor to the
regulation of a natural promoter. Throughout the text,
"context-dependent" transcriptional regulation refers to instances in which the transcriptional properties of a particular factor are influenced either by its position relative to other factors
bound to a given promoter or by the abundance of transcriptional cofactors in a given cell type. It should be emphasized that
context-dependent regulation can be lost when transferring
a binding site to a heterologous promoter, when the position of a
binding site is changed within a natural promoter, or when the cellular
expression levels of critical transcriptional cofactors are altered.
The purpose of this minireview is to describe various ways in which the
specific context of a binding site in a promoter influences the ability of a DNA site-specific transcription factor to regulate gene
expression. For simplicity, we have limited our examples to four
different transcription factors: YY1, lymphocyte enhancer-binding
factor 1 (LEF-1),1 Sp1, and E2F.
YY1 is a ubiquitously expressed mammalian transcription factor that can
function as an activator, a repressor, or an initiator protein,
depending upon promoter context (1). YY1 binds to a specific DNA
sequence element (CCATNTT) via a DNA-binding domain that contains four
C-terminal zinc finger motifs of the Cys2-His2 class. YY1 can bend DNA, and it physically interacts with a variety of
basal and site-specific transcription factors (p300, TATA-binding protein (TBP), TBP-associated factor (TAF) 55, TFIIB, RNA polymerase II, Sp1, c-Myc, and cAMP-regulated enhancer-binding protein (CREB) binding protein. These two characteristics are responsible for the fact
that YY1 function, perhaps to a greater degree than many other
transcription factors, is critically dependent upon promoter structure.
LEF-1 is a member of the T cell factor (TCF)/LEF family of
transcription factors, which in mammals also includes TCF-1, TCF-3, and
TCF-4 (2). Members of this family of transcription factors contain an
85-amino acid DNA-binding domain that is homologous to high mobility
group (HMG) proteins. One subclass of HMG proteins has a high affinity
for DNA structures containing sharply angled bends, four-way junctions,
or crossovers; this subset of factors has little sequence specificity
for DNA binding. LEF-1 is a member of a second subclass of HMG
proteins, which binds to specific sequence elements that are variants
of the consensus CCTTTGAA. The HMG factors are believed to modulate
both gene expression and chromatin structure. The ability of LEF-1 to
bend DNA contributes to its context-dependent activation properties.
Sp1 is a member of a family of transcription factors consisting of Sp1,
Sp2, Sp3, and Sp4 (3). These proteins bind to GC-rich sequences
(e.g. GGGCGG) found in the promoters of many cellular genes.
Sp1 can activate transcription through a variety of mechanisms, functioning as both a basal promoter element and as an upstream activator, depending on promoter context. In many genes lacking TATA
boxes, a proximally positioned Sp1 site serves as the critical determinant of promoter activity and positions the start site of
transcription. However, Sp1 can also enhance transcription from a
distance through DNA looping mediated by protein-protein interactions.
The E2F family of transcription factors functions as heterodimers that
bind a consensus DNA sequence TTTSSCGC (S=C or G) (4). To date six
different mammalian E2F proteins (E2F1-6) have been cloned, and each
of these heterodimerizes with DP1 or DP2 proteins. The E2F proteins
contain central DNA-binding and dimerization domains and (except for
E2F6) a C-terminal transactivation domain. The DP proteins contribute
to the DNA binding activity of the heterodimer but do not contain a
transactivation domain. Nested within the transactivation domain of the
E2F proteins is a protein interaction domain that mediates contact with
the retinoblastoma (Rb) family of proteins (Rb, p107, and p130), which
function to repress transcription. Thus, the interaction of E2F with Rb
determines the activation and repression functions of an E2F
heterodimer bound to a promoter and is critical for mediating cell
cycle-regulated expression of E2F target genes.
Transcription Factor-induced DNA Bending Can Influence Promoter
Activity--
Using simple synthetic promoters, Kim and Shapiro (5)
have shown that a YY1 site can stimulate promoter activity if placed between a binding site for nuclear factor 1 (NF1) and a TATA box but
not if the positions of the YY1 and NF1 sites are switched (Fig.
1A). These results suggest
that the robust activity of the NF1-YY1-TATA promoter is not simply
because of synergy of two weak transcriptional activation domains.
Rather, the authors suggested that a YY1-induced DNA bend brings the
NF1 protein in proximity to the basal transcription complex only if YY1
is placed between NF1 and the TATA box. To test this hypothesis, the
rotational orientation of the YY1-induced bend was changed (by deleting
4 base pairs of DNA between YY1 and the TATA box) so that YY1 bent the
NF1 site in the opposite direction. The synergy between YY1 and NF1 was
lost, supporting the hypothesis that the YY1-induced bend is the
critical determinant in activation of the promoter. However, a
YY1-induced bend does not have the same function at all promoters. For
example, a similar YY1-induced DNA bend represses transcription from
the c-fos promoter (6) and can repress activating protein 1 (AP1)-mediated transcription from a synthetic AP1-YY1-TATA promoter
(5). Thus, these studies show that, because of YY1-mediated DNA
bending, changing the context of a YY1-binding site can dramatically change the effects of YY1 on promoter activity. The ability of LEF-1 to
bend DNA can also influence the transcriptional activity of specific
promoters. For example, the T-cell receptor
Sp1 can also achieve context-dependent transcriptional
activation by altering the structure of DNA. The simian virus 40 (SV40) early promoter is composed of three 21-base pair repeats, with each
repeat containing two binding sites for Sp1. Robust transcriptional activity from this promoter also requires an upstream enhancer that
binds a number of different transcription factors. The 21-base pair
repeats contain an intrinsic DNA bend that can be stabilized by binding
of Sp1 (9). It has been proposed that Sp1-stabilized bending activates
transcription by bringing the factors bound to the upstream enhancer
closer to the basal promoter (Fig. 1B). Another study has
also documented the ability of Sp1 to alter the structure of DNA.
Courey et al. (10) demonstrated that Sp1 proteins bound 1.8 kilobases downstream of a promoter can cooperate with Sp1 bound at the
basal promoter region to synergistically activate transcription. The
proximally and distally bound Sp1 proteins can physically interact to
form a looped DNA structure (11). Therefore, one function of Sp1
appears to be the alteration of DNA structure, resulting in the
recruitment of distally bound activators to a position more proximal to
the basal transcription complex.
Overlapping Binding Sites Can Influence the Response to a
Transcriptional Activator--
The presence of overlapping
transcription factor binding sites often makes it difficult to
determine which factor is mediating transcriptional regulation (Fig.
2). At many promoters, Sp1 sites overlap
with binding sites for the early growth response (Egr) family of
GC-rich DNA-binding transcription factors; binding of Sp1 and Egr1 is
often mutually exclusive. A GC-rich region containing overlapping Sp1
and Egr sites is responsible for phorbol 12-myristate 13-acetate
(PMA)-induced transcription of the platelet-derived growth factor
A-chain promoter (12). Although both proteins can bind to the GC-rich
element, mutational analyses demonstrated that Egr1, not Sp1, is
responsible for PMA-induced activation of the promoter. Sp1 binding to
an overlapping Sp1/Egr site is required for v-Raf-mediated activation
of the multidrug resistance gene 1 transcription in quiescent NIH 3T3
cells (13). In contrast, Egr1 mediates the activation of multidrug
resistance gene 1 transcription by
12-O-tetradecanoylphorbol-13-acetate in K562 cells through the same Sp1/Egr1 element (14). Thus, Sp1 and Egr1 can differentially regulate transcription through the same binding sites, depending on the
cellular environment.
The role of E2F in the regulation of several promoters is influenced by
an overlapping binding site for the transcriptional repressor protein,
CDE-CHR binding factor-1 (CDF-1). Transcription from the B-myb and
cyclin A promoters, both of which contain overlapping E2F and CDF-1
sites, is repressed in the G0 phase of the cell cycle.
Mutational analyses indicated that the E2F site is necessary for
repression of the B-myb promoter (15). The B-myb
promoter strongly binds E2F4, the predominant E2F protein in
G0 phase cells, and only weakly binds CDF-1. In contrast,
CDF-1 binding, but not E2F binding, is critical for repression of the
cyclin A promoter (16), suggesting that CDF-1 mediates this
G0 phase repression. In support of this hypothesis, the
cyclin A promoter is only weakly bound by E2F4 (16).
YY1 has been shown to repress certain promoters because of the
arrangement of overlapping binding sites. For example, YY1 and serum
response factor (SRF) bind to the serum response element (SRE) of the
skeletal Promoter-specific Protein-Protein Interactions Can Influence the
Response to a Transcriptional Activator--
Cooperative interactions
between Sp1 and other DNA-bound transcription factors can result in
context-dependent transcriptional regulation. Mutational
analyses of the human immunodeficiency virus (HIV-1) enhancer indicated
that adjacent binding sites for the nuclear factor of the
The ability of LEF-1 protein-protein interactions to influence
transcription is also promoter-specific because of the interaction of
LEF-1 with two different coactivators,
Several studies have examined functional interactions between E2F and
other DNA-bound transcriptional activators. For example, E2F and Sp1
have been shown to cooperate in activation of the murine thymidine
kinase (tk) promoter (Fig. 3B). Insertion of 20 base pairs between adjacent Sp1- and E2F-binding sites abolishes tk promoter activity, and mutation of either site eliminates
binding of both Sp1 and E2F, demonstrating that these activators
cooperate in DNA binding. Sp1 can bind to the N-terminal region of
E2F1, E2F2, and E2F3, but not to E2F4 or E2F5, suggesting that
cooperativity with Sp1 may be limited to a subset of E2F proteins (26,
27). In support of this hypothesis, Lin et al. (27) have
shown that E2F1, but not E2F4, can synergize with Sp1 in activation of
the hamster dihydrofolate reductase and human DNA polymerase The Structure of the Core Promoter Can Influence the Response to a
Transcriptional Activator--
TATA boxes and initiators (Inrs) are
core promoter elements that mediate formation of a transcription
complex containing RNA polymerase II and other general transcription
factors. Emami et al. (30) found that Sp1 exhibited a strong
preference for promoters containing the terminal
deoxynucleotidyltransferase (TdT) promoter Inr element and that the
addition of a TATA box had only modest effects on activation (Fig.
4). Furthermore, a truncated Sp1 protein containing only the glutamine-rich activation domains exhibited a
strict dependence on the Inr element. Not all activators show this same
preference; e.g. the herpes simplex virus virion protein 16 (VP16) shows a preference for core promoters that contain both a TATA
box and an Inr (Fig. 4) (30), whereas the upstream stimulatory factor
shows a strong preference for a TATA box (31). A TATA box is a binding
site for TBP, one component of the general transcription factor TFIID.
The fact that Sp1 can activate transcription independently of a TATA
box suggests that Sp1 and the TATA box may provide mechanistically redundant functions. In support of this hypothesis, Sp1 has been shown
to activate transcription by contacting TAFII130, another subunit of TFIID (32).
In addition to its role as an upstream activator or repressor of
transcription, YY1 can also serve as an initiator binding protein, most
likely because of its ability to directly recruit TFIIB and RNA
polymerase II (33, 34). However, the levels of YY1-mediated
transcription that are observed in the absence of upstream factors are
quite low. The addition of an Sp1-binding site upstream of the
YY1-binding Inr of the adeno-associated virus P5 (AAV P5) promoter
results in a marked increase in promoter activity (33). This synergy
between YY1 and Sp1 could result from a physical interaction between
the two proteins (35) or the ability of Sp1 to recruit TFIID (32).
Although Sp1 appears to function in concert with a variety of initiator
elements (TdT and AAV P5), it cannot activate transcription in
combination with all Inr elements. The hamster cad promoter
contains two Sp1-binding sites located upstream of a consensus Inr.
Replacement of the cad Inr with two other consensus Inr
sequences resulted in robust transcriptional activity of one construct,
but not the other (36), suggesting that Sp1 can functionally synergize
with some, but not all, initiator binding proteins.
The Cellular Environment Can Influence the Response to a
Transcriptional Activator--
The loss of tumor suppressor genes
and/or the increase in amount of oncogenic transcription factors can
affect the degree to which a site-specific transcription factor can
regulate gene expression. For example, the transcriptional activity of
LEF-1 can vary in different cells because of changes in the subcellular localization of
For many E2F target genes, including E2F1 and
B-myb, E2F functions mainly as a transcriptional repressor
because of the formation of a complex with hypophosphorylated Rb and
associated histone deacetylases (4). However, in many tumor cells, Rb
is either lost or hyperphosphorylated, rendering it nonfunctional. This loss of the repression component of the E2F complex can result in a
switch from E2F-mediated repression to E2F-mediated activation of
target genes (Fig. 5B). For example, malignant gliomas,
which commonly have mutations in the Rb signaling pathway, show
increased E2F1 promoter activity, as compared with normal brain tissue
(40). Mutational analyses indicated that E2F functions as an activator of the E2F1 promoter in these tumor cells. Similarly, others
have shown that the E2F-binding site in the B-myb promoter
is converted to a positive element in F9 embryonal carcinoma cells,
which contain high levels of free E2F (41).
The activity of YY1 can also be influenced by the cellular
environment. For example, the c-Myc protein can associate with YY1 and
inhibit both its transcriptional activation and repression properties
(42). In cells containing low amounts of c-Myc, such as quiescent 3T3
fibroblasts, YY1 is free to regulate transcription (43). In contrast,
after mitogenic stimulation of 3T3 cells, levels of c-Myc increase and
YY1 is recruited into a c-Myc·YY1 complex. Although the c-Myc·YY1
complex can bind to YY1 sites, it does not possess transcriptional
regulatory activity. This suggests that in tumor cells which contain
high levels of c-Myc, such as Burkitt's lymphomas, YY1 may not be able
to activate or repress transcription.
We have provided examples that highlight the importance of
studying the function of transcription factors in a natural promoter context. For instance, the transfer of a binding site for a protein that induces DNA bending from its position in a natural promoter to a
random position in a synthetic promoter can result in a
misinterpretation of the role of that factor in transcriptional
regulation (Fig. 1). The presence of overlapping transcription factor
binding sites at a promoter can also result in context-specific
regulation (Fig. 2). Therefore, determination of the function of a
protein at a particular promoter requires consideration of the
sequences flanking the binding sites. The ability of a transcription
factor to function as an activator or repressor of transcription and
the degree to which a promoter responds to a factor can also vary
depending upon the presence of other site-specific transcription
factors (Fig. 3). Some upstream activators cooperate with specific core promoter elements to provide robust transcriptional activation (Fig.
4). Finally, transcriptional activity can clearly be influenced by the
cellular environment in which the assays are performed (Fig. 5). We
believe that the five mechanisms described in this review provide
general models that are applicable to many site-specific transcriptional regulators. In conclusion, we suggest that, to the
greatest extent possible, the function of a transcription factor-binding site should be studied in the context of a natural promoter and in cells that are most physiologically relevant to the
hypothesis being tested.
![]()
INTRODUCTION
TOP
INTRODUCTION
Five Mechanisms by Which...
Conclusions
REFERENCES
![]()
Five Mechanisms by Which Context-dependent
Transcriptional Activation Can Be Achieved
TOP
INTRODUCTION
Five Mechanisms by Which...
Conclusions
REFERENCES
(TCR
) enhancer
contains a LEF-1 site flanked on either side by a CREB and an
Ets-binding site; activation of the TCR
enhancer requires proteins
that bind all three sites (7). Increasing the spacing between the LEF-1
site and either the Ets or CREB site reduces transcriptional
activation, suggesting that the precise distance between the sites is
critical. These studies led to the hypothesis that DNA bending caused
by LEF-1 promotes interactions between the proteins bound to the CREB
and Ets sites. In support of this model, further studies showed that
placing the Ets and CREB sites next to each other abrogates the need
for LEF-1 (7). Also, studies using variant LEF-1-binding sites show a
correlation between the extent of DNA bending and transcriptional
activation of the TCR
enhancer, supporting the hypothesis that
LEF-1-induced DNA bending contributes to promoter activity (8).

View larger version (12K):
[in a new window]
Fig. 1.
Transcription factor-induced DNA bending can
influence promoter activity. A, DNA bending induced by
a properly positioned YY1 protein brings NF1 closer to the basal
transcription complex (e.g. TBP); placement of YY1 upstream
of NF1 abolishes YY1-mediated activation. B, Sp1-mediated
DNA bending at the SV40 early promoter brings the enhancer closer to
the basal promoter complex; mutation of the Sp1 sites (indicated by the
Xs) reduces DNA bending and transcriptional
activation.

View larger version (19K):
[in a new window]
Fig. 2.
Overlapping binding sites can influence the
response to a transcriptional activator. Overlapping binding sites
for Sp1 and Egr, E2F and CDF-1 (CDE), and YY1 and SRF
(SRE) can result in competitive binding. Therefore, the
contribution of sequences flanking a binding site can be important in
determining the function of a factor at a particular promoter.
-actin promoter in a mutually exclusive manner (17, 18).
Normally, YY1 blocks access of SRF and prevents activation of the
promoter. However, under conditions in which YY1 DNA binding activity
decreases (e.g. during myogenic differentiation), SRF has
free access to its binding site, and transcription from the skeletal
-actin promoter is increased. The SRE in the c-fos promoter is also bound by both YY1 and SRF (19). The binding of these
two factors in primary chicken muscle cells is mutually exclusive, and
YY1 can block the SRF-mediated induction of the c-fos
promoter. Thus, removal of a YY1 site (CCATNTT) from within an SRE
(CC(A/T)6GG) can result in a misunderstanding of the role of YY1 in the regulation of a particular gene.
light
chain enhancer in B cells (NF-
B) and Sp1 are sufficient to direct
mitogen-stimulated transcription (20). However, mutation of either the
NF-
B or the Sp1 site or the addition of 5 base pairs between the two
sites abolishes activation and binding of both proteins. These studies
demonstrate that a protein-protein interaction between NF-
B and Sp1
can result in cooperative DNA binding and synergistic activation of
promoters containing appropriately spaced binding sites. A
protein-protein interaction between Sp1 and the octamer-binding
transcription factor (OTF-1/Oct-1) mediates transcriptional activation
of the upstream U2 small nuclear RNA gene enhancer (21, 22). Sp1 and
OTF-1/Oct-1 cooperate in DNA binding and synergistic activation, both
of which become more pronounced when the Sp1 site is combined with a
low affinity OTF-1/Oct-1-binding site (Fig.
3A). The cooperativity between
OTF-1/Oct-1 and Sp1 is distance-dependent; the addition of
only 15 base pairs between the Sp1 site and a low affinity OTF-1/Oct-1
site reduced activation 5-fold. The erythroid-specific GATA binding
factor (GATA) family of transcriptional activators can also synergize
with Sp1 at the erythroid pyruvate kinase and glycophorin B promoters
(23). In contrast, Sp1 and GATA do not synergize at a
maj-globin-derived promoter, although it contains
similarly spaced Sp1 and GATA sites. The exact promoter features that
specify GATA and Sp1 cooperativity have not yet been determined. Taken
together, these results clearly show that the presence of other
site-specific DNA-binding proteins can greatly influence the ability of
Sp1 to activate transcription.

View larger version (16K):
[in a new window]
Fig. 3.
Promoter-specific protein-protein
interactions can influence the response to a transcriptional
activator. A, synergy with Sp1 is needed for robust
activation of a U2 small nuclear RNA enhancer containing a low affinity
Oct-1 site (indicated by the gray shading); a
high affinity Oct-1 site does not require synergy with Sp1.
B, E2F can synergize with Sp1 in activation of the murine
tk promoter. However, insertion of 20 base pairs between the
two sites or mutation of either the Sp1 or the E2F site results in loss
of binding of both factors and loss of activation.
-catenin and ally of LEF-1
(ALY). Each of these coactivators enhances the ability of LEF-1 to
activate a specific subset of promoters (24, 25). For example,
multimerized LEF-1 sites cloned upstream of the c-fos minimal promoter can confer robust activation by LEF-1·
-catenin complexes, but this same promoter construct is not responsive to
LEF-1·ALY complexes. In contrast, the TCR
enhancer is highly responsive to LEF-1·ALY complexes but cannot be activated by
LEF-1·
-catenin complexes. The circumstances that determine the
ability of LEF-1·coactivator complexes to activate some, but not all,
promoters are not yet understood but appear to be promoter
context-dependent.
promoters. Furthermore, E2F1 can synergize with Sp1, but not Sp3, in
activation of the c-myc promoter (28), suggesting that
cooperativity is also limited to a subset of the Sp1 family of
proteins. Additional studies have shown that YY1 and the CCAAT-binding
factor NF-Y can also cooperate with E2F to mediate growth-regulated
transcription (29). In fact, many E2F-regulated promoters contain Sp1,
YY1, and/or NF-Y binding sites, suggesting a great potential for
context-dependent E2F activities.

View larger version (16K):
[in a new window]
Fig. 4.
The structure of the core promoter can
influence the response to a transcriptional activator.
A, core promoters containing the TdT Inr can be activated by
Sp1, regardless of the presence of a TATA box. However, mutation of the
Inr greatly reduces activation by Sp1. In contrast, VP16 can
efficiently activate all core promoters but shows maximal activation of
core promoters containing both an Inr and a TATA box.
-catenin (Fig.
5A). LEF-1, which does not
contain an activation domain, cannot stimulate transcription from
multiple binding sites cloned upstream of a minimal promoter. However, LEF-1·
-catenin complexes can stimulate transcription because of a
transcriptional activation domain in
-catenin (24).
-Catenin is
normally found in the cytoplasm complexed with the adenomatous polyposis coli (APC) protein. Mutations in APC (found in a large percentage of colon cancer cells) result in disruption of the complex,
allowing
-catenin to translocate to the nucleus and bind to
TCF/LEF-1 proteins (37, 38). Thus, certain LEF target genes, such as
c-myc, are only activated by LEF family members in tumor
cells that contain high levels of nuclear
-catenin (39).

View larger version (13K):
[in a new window]
Fig. 5.
The cellular environment can
influence the response to a transcriptional activator.
A, the loss of the APC tumor suppressor protein in colon
cancer cells causes an increase in
-catenin·LEF-1 complexes and
activation of LEF-1 target genes. B, the loss of the Rb
tumor suppressor protein in many types of tumor cells can result in the
switch of E2F function from a repressor to an activator, resulting in
constitutive activation of E2F target genes. HDAC, histone
deacetylases.
![]()
Conclusions
TOP
INTRODUCTION
Five Mechanisms by Which...
Conclusions
REFERENCES
| |
FOOTNOTES |
|---|
* This minireview will be reprinted in the 1999 Minireview Compendium, which will be available in December, 1999.
To whom correspondence should be addressed: McArdle Laboratory,
1400 University Ave., Madison, WI 53706. Tel.: 608-262-2071; Fax:
608-262-2824; E-mail: farnham@oncology.wisc.edu.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
LEF-1, lymphocyte
enhancer-binding factor 1;
TBP, TATA-binding protein;
TAF, TBP-associated factor;
CREB, cAMP-regulated enhancer-binding protein;
TCF, T cell factor;
HMG, high mobility group;
Rb, retinoblastoma;
NF1, nuclear factor 1;
AP1, activating protein 1;
TCR
, T-cell receptor
;
SV40, simian virus 40;
Egr, early growth response;
PMA, phorbol
12-myristate 13-acetate;
CDF-1, CDE-CHR binding factor-1;
SRF, serum
response factor;
SRE, serum response element;
NF-
B, nuclear factor
of the
light chain enhancer in B cells;
OTF-1/Oct-1, octamer-binding transcription factor;
GATA, GATA-binding factor;
ALY, ally of LEF-1;
TK, thymidine kinase;
Inr, initiator;
TdT, terminal
deoxynucleotidyltransferase;
VP16, herpes simplex virus virion protein
16;
AAV P5, adeno-associated virus P5;
APC, adenomatous polyposis
coli.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Shi, Y., Lee, J.-S., and Galvin, K. M. (1997) Biochim. Biophys. Acta 1332, F49-F66[Medline] [Order article via Infotrieve] |
| 2. | Bienz, M. (1998) Curr. Opin. Cell Biol. 10, 366-372[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Lania, L., Majello, B., and De Luca, P. (1997) Int. J. Biochem. Cell Biol. 29, 1313-1323[CrossRef][Medline] [Order article via Infotrieve] |
| 4. |
Dyson, N.
(1998)
Genes Dev.
12,
2245-2262 |
| 5. |
Kim, J.,
and Shapiro, D. J.
(1996)
Nucleic Acids Res.
24,
4341-4348 |
| 6. |
Natesan, S.,
and Gilman, M. Z.
(1993)
Genes Dev.
7,
2497-2509 |
| 7. | Giese, K., and Grosschedl, R. (1993) EMBO J. 12, 4667-4676[Medline] [Order article via Infotrieve] |
| 8. |
Giese, K.,
Pagel, J.,
and Grosschedl, R.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
12845-12850 |
| 9. | Sun, D., and Hurley, L. H. (1994) Biochemistry 33, 9578-9587[CrossRef][Medline] [Order article via Infotrieve] |
| 10. | Courey, A. J., Holtzman, D. A., Jackson, S. P., and Tjian, R. (1989) Cell 59, 827-836[CrossRef][Medline] [Order article via Infotrieve] |
| 11. |
Su, W.,
Jackson, S.,
Tjian, R.,
and Echols, H.
(1991)
Genes Dev.
5,
820-826 |
| 12. |
Khachigian, L. M.,
Williams, A. J.,
and Collins, T.
(1995)
J. Biol. Chem.
270,
27679-27686 |
| 13. | Miltenberger, R. J., Farnham, P. J., Smith, D. E., Stommel, J. M., and Cornwell, M. M. (1995) Cell Growth Differ. 6, 549-556[Abstract] |
| 14. | McCoy, C., Smith, D. E., and Cornwell, M. M. (1995) Mol. Cell. Biol. 15, 6100-6108[Abstract] |
| 15. |
Lucibello, F. C.,
Liu, N.,
Zwicker, J.,
Gross, C.,
and Muller, R.
(1997)
Nucleic Acids Res.
25,
4921-4925 |
| 16. | Liu, N., Lucibello, F. C., Engeland, K., and Muller, R. (1998) Oncogene 16, 2957-2963[CrossRef][Medline] [Order article via Infotrieve] |
| 17. |
Lee, T.-C.,
Chow, K.-L.,
Fang, P.,
and Schwartz, R. J.
(1991)
Mol. Cell. Biol.
11,
5090-5100 |
| 18. |
Lee, T.-C.,
Shi, Y.,
and Schwartz, R. J.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
9814-9818 |
| 19. |
Gualberto, A.,
LePage, D.,
Pons, G.,
Mader, S. L.,
Park, K.,
Atchison, M. L.,
and Walsh, K.
(1992)
Mol. Cell. Biol.
12,
4209-4214 |
| 20. | Perkins, N. D., Edwards, N. L., Duckett, C. S., Agranoff, A. B., Schmid, R. M., and Nabel, G. J. (1993) EMBO J. 12, 3551-3558[Medline] [Order article via Infotrieve] |
| 21. |
Strom, A. C.,
Forsberg, M.,
Lillhager, P.,
and Westin, G.
(1996)
Nucleic Acids Res.
24,
1981-1986 |
| 22. |
Janson, L.,
and Pettersson, U.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
4732-4736 |
| 23. |
Gregory, R. C.,
Taxman, D. J.,
Seshasayee, D.,
Kensinger, M. H.,
Bieker, J. J.,
and Woychowski, D. M.
(1996)
Blood
87,
1793-1801 |
| 24. |
Hsu, S.-C.,
Galceran, J.,
and Grosschedl, R.
(1998)
Mol. Cell. Biol.
18,
4807-4818 |
| 25. |
Bruhn, L.,
Munnerlyn, A.,
and Grosschedl, R.
(1997)
Genes Dev.
11,
640-653 |
| 26. | Karlseder, J., Rotheneder, H., and Wintersberger, E. (1996) Mol. Cell. Biol. 16, 1659-1667[Abstract] |
| 27. | Lin, S.-Y., Black, A. R., Kostic, D., Pajovic, S., Hoover, C. N., and Azizkhan, J. C. (1996) Mol. Cell. Biol. 16, 1668-1675[Abstract] |
| 28. | Majello, B., De Luca, P., Suske, G., and Lania, L. (1995) Oncogene 10, 1841-1848[Medline] [Order article via Infotrieve] |
| 29. |
van Ginkel, P. R.,
Hsiao, K.-M.,
Schjerven, H.,
and Farnham, P. J.
(1997)
J. Biol. Chem.
272,
18367-18374 |
| 30. | Emami, K. H., Navarre, W. W., and Smale, S. T. (1995) Mol. Cell. Biol. 15, 5906-5916[Abstract] |
| 31. | Luo, X., and Sawadogo, M. (1996) Mol. Cell. Biol. 16, 1367-1375[Abstract] |
| 32. |
Saluja, D.,
Vassallo, M. F.,
and Tanese, N.
(1998)
Mol. Cell. Biol.
18,
5734-5743 |
| 33. | Seto, E., Shi, Y., and Shenk, T. (1991) Nature 354, 241-245[CrossRef][Medline] [Order article via Infotrieve] |
| 34. |
Usheva, A.,
and Shenk, T.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
13571-13576 |
| 35. |
Lee, J.-S.,
Galvin, K. M.,
and Shi, Y.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
6145-6149 |
| 36. |
Kollmar, R.,
Sukow, K. A.,
Sponagle, S. K.,
and Farnham, P. J.
(1994)
J. Biol. Chem.
269,
2252-2257 |
| 37. |
Morin, P. J.,
Sparks, A. B.,
Korinek, V.,
Barker, N.,
Clevers, H.,
Vogelstein, B.,
and Kinzler, K. W.
(1997)
Science
275,
1787-1790 |
| 38. |
Korinek, V.,
Barker, N.,
Morin, P. J.,
van Wichen, D.,
de Weger, R.,
Kinzler, K. W.,
Vogelstein, B.,
and Clevers, H.
(1997)
Science
275,
1784-1787 |
| 39. |
He, T.-C.,
Sparks, A. B.,
Rago, C.,
Hermeking, H.,
Zawel, L.,
da Costa, L. T.,
Morin, P. J.,
Vogelstein, B.,
and Kinzler, K. W.
(1998)
Science
281,
1509-1512 |
| 40. | Parr, M. J., Manome, Y., Tanaka, T., Wen, P., Kufe, D. W., Kaelin, W. G. J., and Fine, H. A. (1997) Nat. Med. 3, 1145-1149[CrossRef][Medline] [Order article via Infotrieve] |
| 41. | Bennett, J. D., Farlie, P. G., and Watson, R. J. (1996) Oncogene 13, 1073-1082[Medline] [Order article via Infotrieve] |
| 42. |
Shrivastava, A.,
Saleque, S.,
Kaplana, G. V.,
Artandi, S.,
Goff, S. P.,
and Calame, K.
(1993)
Science
262,
1889-1892 |
| 43. |
Shrivastava, A., Yu, J.,
Artandi, S.,
and Calame, K.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
10638-10641 |
This article has been cited by other articles:
![]() |
X. Xu, M. Bieda, V. X. Jin, A. Rabinovich, M. J. Oberley, R. Green, and P. J. Farnham A comprehensive ChIP chip analysis of E2F1, E2F4, and E2F6 in normal and tumor cells reveals interchangeable roles of E2F family members Genome Res., November 1, 2007; 17(11): 1550 - 1561. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Barrero, R. Gonzalez-Bayon, J. C. del Pozo, M. R. Ponce, and J. L. Micol INCURVATA2 Encodes the Catalytic Subunit of DNA Polymerase {alpha} and Interacts with Genes Involved in Chromatin-Mediated Cellular Memory in Arabidopsis thaliana PLANT CELL, September 1, 2007; 19(9): 2822 - 2838. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Onuma, B. T. Vander Kooi, J. N. Boustead, J. K. Oeser, and R. M. O'Brien Correlation between FOXO1a (FKHR) and FOXO3a (FKHRL1) Binding and the Inhibition of Basal Glucose-6-Phosphatase Catalytic Subunit Gene Transcription by Insulin Mol. Endocrinol., November 1, 2006; 20(11): 2831 - 2847. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Qin, R. Kishore, C. M. Dolan, M. Silver, A. Wecker, C. N. Luedemann, T. Thorne, A. Hanley, C. Curry, L. Heyd, et al. Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF PNAS, July 18, 2006; 103(29): 11015 - 11020. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Liu and W.-H. Lee CtIP Activates Its Own and Cyclin D1 Promoters via the E2F/RB Pathway during G1/S Progression Mol. Cell. Biol., April 15, 2006; 26(8): 3124 - 3134. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-K. Youn, S.-H. Kim, D. Y. Lee, S. H. Song, I.-Y. Chang, J.-W. Hyun, M.-H. Chung, and H. J. You Cadmium Down-regulates Human OGG1 through Suppression of Sp1 Activity J. Biol. Chem., July 1, 2005; 280(26): 25185 - 25195. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Seenundun and B. Robaire Cloning and Characterization of the 5{alpha}-Reductase Type 2 Promoter in the Rat Epididymis Biol Reprod, April 1, 2005; 72(4): 851 - 861. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Thomas, D.-Y. Sung, J. Yang, K. Johnson, W. Thompson, C. Millette, J. McCarrey, A. Breitberg, R. Gibbs, and W. Walker Identification, Characterization, and Functional Analysis of Sp1 Transcript Variants Expressed in Germ Cells During Mouse Spermatogenesis Biol Reprod, April 1, 2005; 72(4): 898 - 907. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kirmizis and P. J. Farnham Genomic Approaches That Aid in the Identification of Transcription Factor Target Genes Experimental Biology and Medicine, September 1, 2004; 229(8): 705 - 721. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Wray, M. W. Hahn, E. Abouheif, J. P. Balhoff, M. Pizer, M. V. Rockman, and L. A. Romano The Evolution of Transcriptional Regulation in Eukaryotes Mol. Biol. Evol., September 1, 2003; 20(9): 1377 - 1419. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Truscott, L. Raynal, P. Premdas, B. Goulet, L. Leduy, G. Berube, and A. Nepveu CDP/Cux Stimulates Transcription from the DNA Polymerase {alpha} Gene Promoter Mol. Cell. Biol., April 15, 2003; 23(8): 3013 - 3028. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. Nichols, T. Itoh, F. Zolezzi, S. Hutsell, and S. Linn Basal transcriptional regulation of human damage-specific DNA-binding protein genes DDB1 and DDB2 by Sp1, E2F, N-myc and NF1 elements Nucleic Acids Res., January 15, 2003; 31(2): 562 - 569. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kirmizis, S. M. Bartley, and P. J. Farnham Identification of the Polycomb Group Protein SU(Z)12 as a Potential Molecular Target for Human Cancer Therapy Mol. Cancer Ther., January 1, 2003; 2(1): 113 - 121. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. L. Wilson, P. J. McFie, and W. J. Roesler Different Transcription Factor Binding Arrays Modulate the cAMP Responsivity of the Phosphoenolpyruvate Carboxykinase Gene Promoter J. Biol. Chem., November 8, 2002; 277(46): 43895 - 43902. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. E. Uveges, Y. Shan, B. E. Kramer, D. C. Wight, and L. M. Parysek Intron 1 Is Required for Cell Type-Specific, But Not Injury-Responsive, Peripherin Gene Expression J. Neurosci., September 15, 2002; 22(18): 7959 - 7967. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Stevens, L. Mariconti, P. Rossignol, C. Perennes, R. Cella, and C. Bergounioux Two E2F Sites in the Arabidopsis MCM3 Promoter Have Different Roles in Cell Cycle Activation and Meristematic Expression J. Biol. Chem., August 30, 2002; 277(36): 32978 - 32984. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Ayala, R. S. Streeper, C. A. Svitek, J. K. Goldman, J. K. Oeser, and R. M. O'Brien Accessory Elements, Flanking DNA Sequence, and Promoter Context Play Key Roles in Determining the Efficacy of Insulin and Phorbol Ester Signaling through the Malic Enzyme and Collagenase-1 AP-1 Motifs J. Biol. Chem., July 26, 2002; 277(31): 27935 - 27944. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Dumont, S. Dremier, I. Pirson, and C. Maenhaut Cross signaling, cell specificity, and physiology Am J Physiol Cell Physiol, July 1, 2002; 283(1): C2 - C28. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Tanno, A. Negroni, R. Vitali, M. C. Pirozzoli, V. Cesi, C. Mancini, B. Calabretta, and G. Raschella Expression of Insulin-like Growth Factor-binding Protein 5 in Neuroblastoma Cells Is Regulated at the Transcriptional Level by c-Myb and B-Myb via Direct and Indirect Mechanisms J. Biol. Chem., June 21, 2002; 277(26): 23172 - 23180. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-E. Chaboute, B. Clement, and G. Philipps S Phase and Meristem-specific Expression of the Tobacco RNR1b Gene Is Mediated by an E2F Element Located in the 5' Leader Sequence J. Biol. Chem., May 10, 2002; 277(20): 17845 - 17851. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. N. Keembiyehetty, R. P. Candelaria, G. Majumdar, R. Raghow, A. Martinez-Hernandez, and S. S. Solomon Paradoxical Regulation of Sp1 Transcription Factor by Glucagon Endocrinology, April 1, 2002; 143(4): 1512 - 1520. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kido, A. Doerks, M. Lochelt, and R. M. Flugel Identification and Functional Characterization of an Intragenic DNA Binding Site for the Spumaretroviral trans-Activator in the Human p57Kip2 Gene J. Biol. Chem., March 29, 2002; 277(14): 12032 - 12039. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. E. Carlini, M. J. Getz, A. R. Strauch, and R. J. Kelm Jr. Cryptic MCAT Enhancer Regulation in Fibroblasts and Smooth Muscle Cells. SUPPRESSION OF TEF-1 MEDIATED ACTIVATION BY THE SINGLE-STRANDED DNA-BINDING PROTEINS, Puralpha , Purbeta , and MSY1 J. Biol. Chem., March 1, 2002; 277(10): 8682 - 8692. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. D'Alonzo, N. Selvamurugan, G. Karsenty, and N. C. Partridge Physical Interaction of the Activator Protein-1 Factors c-Fos and c-Jun with Cbfa1 for Collagenase-3 Promoter Activation J. Biol. Chem., January 4, 2002; 277(1): 816 - 822. [Abstract] [Full Text] |
||||
![]() |
R. C. Brown, S. Pattison, J. van Ree, E. Coghill, A. Perkins, S. M. Jane, and J. M. Cunningham Distinct Domains of Erythroid Kruppel-Like Factor Modulate Chromatin Remodeling and Transactivation at the Endogenous {beta}-Globin Gene Promoter Mol. Cell. Biol., January 1, 2002; 22(1): 161 - 170. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Nagano, H. Furuhashi, T. Inaba, and Y. Sasaki A novel class of plant-specific zinc-dependent DNA-binding protein that binds to A/T-rich DNA sequences Nucleic Acids Res., October 15, 2001; 29(20): 4097 - 4105. [Abstract] [Full Text] [PDF] |
||||